「reporting」の検索結果

Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.

日本語の概要は準備中です。原文の説明を表示しています。

Classify constitutional (germline) copy number variants for clinical reporting using the 2019 ACMG/ClinGen technical standards points-based framework, with ClassifyCNV and AnnotSV for semi-automated scoring. Covers the separate copy-number-loss and copy-number-gain rubrics, the five-tier classification, ClinGen haploinsufficiency/triplosensitivity and dosage-sensitive regions, de novo and segregation evidence, and population-frequency benign evidence. Use when assigning pathogenic/likely-pathogenic/VUS/likely-benign/benign to a constitutional CNV, scoring a CNV against ACMG/ClinGen criteria, or distinguishing the automatable evidence from the case-specific evidence requiring manual input.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates tumor mutational burden from WES/WGS/panel data with Friends of Cancer Research harmonization equations, per-assay calibration (FDA 10/Mb = 7.8 TSO500 = 8.4 OncomineTML), synonymous/indel/germline filtering, hypermutator tiering, blood TMB, and integration with HLA-LOH and neoantigen quality (Luksza 2017 fitness). Use when assessing ICI eligibility under tumor-specific cutoffs (McGrail 2021), comparing tissue vs bTMB, or auditing TMB-H reporting against ESMO 2024 and FDA pembrolizumab pan-tumor 2020.

日本語の概要は準備中です。原文の説明を表示しています。

Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Constructs and validates polygenic risk scores using LDpred2-auto, SBayesRC, MegaPRS, PRS-CS, PROSPER, MUSSEL, BridgePRS, JointPRS, PRSmix, or PGS Catalog Calculator with ancestry-aware reference panels (HapMap3, UKB-LD), ancestry-conditional calibration, and PRS-RS reporting standards. Use when computing PRS for cohorts, applying absolute-risk transformation, assessing cross-ancestry portability (Martin 2017 / Ding 2023 continuous ancestry), or auditing PRS manuscripts against the 22-item PRS-RS reviewer checklist.

日本語の概要は準備中です。原文の説明を表示しています。

Treats a ctDNA assay as a molecule-counting experiment at the Poisson edge and builds its analytical-validation case the measurement-science way. Covers the genome-equivalent currency (~330 haploid copies/ng), the lambda = input_GE x VAF sampling ceiling (lambda>=3 for ~95% detection), the error-suppression ladder (raw NGS ~1e-3 -> single-strand UMI ~1e-4/1e-5 -> duplex <1e-7), the CLSI EP17 LoB/LoD/LoD95/LoQ framework, the per-locus-vs-panel-integrated LoD distinction that lets bespoke MRD reach ppm, contrived/SEQC2 reference standards, and honest LoD reporting conditioned on input mass + consensus depth + replicate detection rate. Use when stating or trusting a sensitivity claim, designing a dilution-series validation, deciding how many genome equivalents are needed at a target VAF, choosing a single-locus vs panel-integrated LoD, or auditing a "detects 0.1% VAF" claim.

日本語の概要は準備中です。原文の説明を表示しています。

Automated cell behavior analysis from microscopy or XR lab recordings. Classifies cell motion phenotypes (migration, proliferation, apoptosis, division, quiescence), computes population-level quantitative metrics (growth rate, migration velocity, directionality index), and emits structured JSON for downstream reporting, plotting, or ELN integration.

日本語の概要は準備中です。原文の説明を表示しています。

Use when writing C# / VB.NET / F# code that reads, writes, manipulates, or exports Excel (.xlsx / .xls) files, generates PDF or HTML from Excel, or produces data-driven reports with FlexCel Studio for .NET (TMS Software). Triggers include Excel/xlsx from C#, XlsFile, FlexCelReport, FlexCelPdfExport, FlexCelHtmlExport, FlexCelImgExport, ExcelFile, PdfWriter, .NET Excel export, ASP.NET Excel generation, .NET MAUI Excel, Native AOT + Excel, and Excel reporting from .NET.

日本語の概要は準備中です。原文の説明を表示しています。

Use when writing Delphi / FreePascal / C++Builder code that reads, writes, manipulates, or exports Excel (.xlsx / .xls) files, generates PDF or HTML from Excel, or produces data-driven reports with FlexCel Studio for VCL and FireMonkey (TMS FlexCel). Triggers include Excel/xlsx from Delphi, TXlsFile, TFlexCelReport, TFlexCelPdfExport, TFlexCelHtmlExport, FireMonkey Excel export, Lazarus Excel, and Excel reporting from Pascal.

日本語の概要は準備中です。原文の説明を表示しています。

Guides AI agents through Senzing entity resolution workflows using the Senzing MCP server. Covers data mapping to Senzing format, SDK code generation (Python, Java, C#, Rust, TypeScript/Node.js), documentation search, error troubleshooting, sample data access, reporting and visualization, SDK setup guides, and V3-to-V4 migration. Use when working with entity resolution, record matching, record linkage, deduplication, Senzing SDK integration, data mapping for Senzing ingestion, or troubleshooting Senzing error codes. Also use when the user mentions matching records across data sources, finding duplicate entities, identity resolution, master data management, or needs to resolve who is who across datasets.

日本語の概要は準備中です。原文の説明を表示しています。

Creates stakeholder communications including investor updates, board reports, annual impact reports, and partner communications aligned with B Corp PSG standards. Use when user asks about investor relations, board communications, stakeholder reporting, impact reports, annual reports, or partner/supplier communications.

日本語の概要は準備中です。原文の説明を表示しています。

Marketing operations manager handling budget planning, financial reporting, meeting preparation and follow-up, vendor management, and administrative workflows for marketing and communications departments. Designed for SME leaders who need to minimize time spent on operational overhead.

日本語の概要は準備中です。原文の説明を表示しています。

Use for every progress update, status report, problem explanation, ETA, review, acceptance, or completion report to the operator/owner, especially when they ask “到哪了”, “什么问题”, “做了什么”, “结果呢”, “还要多久”, or “说人话”. Translate technical evidence into visible or operational outcomes before details.

日本語の概要は準備中です。原文の説明を表示しています。

Use when picking a failure-reporting strategy — exceptions vs Result types, recoverable vs not, retry / circuit-breaker / graceful degradation — decision framework only, catalogues externalized.

日本語の概要は準備中です。原文の説明を表示しています。

Initialize the standard Interlateral two-agent CLI mesh from a bootstrap agent by running me.sh, launching Claude Opus 4.7 plus Codex 5.5, proving live ACK, and waiting for "Reporting for Duty!". The bootstrap agent is not part of the mesh.

日本語の概要は準備中です。原文の説明を表示しています。

Toolkit for styling artifacts with a theme. These artifacts can be slides, docs, reportings, HTML landing pages, etc. There are 10 pre-set themes with colors/fonts that you can apply to any artifact that has been creating, or can generate a new theme on-the-fly.

日本語の概要は準備中です。原文の説明を表示しています。

Load this skill whenever you are filing, reviewing, or generating accessibility bug reports — whether from automated tool output, manual testing, user reports, or testing with disabled people. The purpose of this skill is to make accessibility findings easier to report accurately, connect them to real people and tasks, and let developers reproduce, understand, and fix them without unnecessary back-and-forth. Absolutely always describe the barrier and its task impact before citing a WCAG criterion. Under no circumstances guess a disability diagnosis, treat automated tool output as a conformance conclusion, or expose secrets/personal data in a report.

日本語の概要は準備中です。原文の説明を表示しています。

Load this skill when configuring or reviewing CI/CD pipelines, GitHub Actions workflows, or automated testing setups. Ensures accessibility regressions are caught before code reaches production by enforcing quality gates, structured reporting, and layered automated + manual testing across all pages and user preferences.

日本語の概要は準備中です。原文の説明を表示しています。

[Documentation] Use when (re)generating the DERIVED technical spec view over code + tests, or reporting canonical §8 TC/test-code drift. A GENERATOR — it projects code + tests into a regenerable per-component view and NEVER authors business content. Modes generate|audit|sync. Per-mode procedure lives in references/{author,sync}.md.

日本語の概要は準備中です。原文の説明を表示しています。

[Git] Use when you need to resolve git merge/cherry-pick/rebase conflicts with backup, analysis, and reporting.

日本語の概要は準備中です。原文の説明を表示しています。

Validate database schema, migrations, indexes, and query behavior with structured pass/fail reporting.

日本語の概要は準備中です。原文の説明を表示しています。

Prioritize vulnerability remediation using KEV-style exploitation context plus asset criticality. Use for CVE triage, patch order decisions, and remediation reporting.

日本語の概要は準備中です。原文の説明を表示しています。